Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents

Investigative Radiology

Volumn 41, Issue 3, 2006, Pages 222-228

  Giesel, Frederik L ^a,b   Von Tengg Kobligk, Hendrik ^a   Wilkinson, Iain D ^b   Siegler, Peter ^a   Von Der Lieth, Claus W ^a   Frank, Martin ^a   Lodemann, Klaus P ^c   Essig, Marco ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Bracco Altana Pharma   (Germany)

Author keywords

Contrast media; Human serum albumin; Magnetic resonance imaging; Relaxation rate

Indexed keywords

CONTRAST MEDIUM; DOCKING PROTEIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; HUMAN SERUM ALBUMIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; DRUG DERIVATIVE; GADOBENIC ACID; GADOLINIUM DO3A BUTRIOL; GADOLINIUM-DO3A-BUTRIOL; MEGLUMINE; ORGANOMETALLIC COMPOUND; SERUM ALBUMIN;

ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; DRUG BINDING SITE; DRUG PROTEIN BINDING; HUMAN; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; CHEMICAL STRUCTURE; COMPARATIVE STUDY; METHODOLOGY;

CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MODELS, MOLECULAR; ORGANOMETALLIC COMPOUNDS; SERUM ALBUMIN;

EID: 33646197837     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000192421.81037.d5     Document Type: Article

References (42)

1. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003;14:426-435.
2. Knopp MV, von Tengg-Kobligk H, Floemer F, et al. Contrast agents for MRA: future directions. J Magn Reson Imaging. 1999;10:314-316.
3. Vander Elst L, Laurent S, Muller RN. Multinuclear magnetic resonance characterization of paramagnetic contrast agents. The manifold effects of concentration and counterions. Invest Radiol. 1998;33:828-834.
4. Goyen M, Edelman M, Perreault P, et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology. 2005;14.
5. Perreault P, Edelman MA, Baum RA, et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology. 2003;229:811-820.
6. Vander Elst L, Laurent S, Bintoma HM, et al. Albumin-bound MRI contrast agents: the dilemma of the rotational correlation time. MAGMA. 2001;12(2-3):135-140.
7. Corti MC, Guralnik JM, Salive ME, et al. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA. 1994;272:1036-1042.
8. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
9. Parmelee DJ, Walovitch RC, Ouellet HS, et al. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol. 1997;32:741-747.
10. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies. Invest Radiol. 2002;37:706-715.
11. Paetsch I, Huber ME, Bornstedt A, et al. Improved three-dimensional free-breathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement. J Magn Reson Imaging. 2004;20:288-293.
12. Essig M, Waschkies M, Wenz F, et al. Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR imaging: initial results. Radiology. 2003;228:193-199.
13. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol. 2005;35:501-510.
14. Dufour DR. Gender related differences in liver function and integrity tests. Clin Chem. 1998;44(suppl 6):A137.
15. Doumas BT, Peters T Jr. Serum and urine albumin: a progress report on their measurement and clinical significance. Clin Chim Acta. 1997;258:3-20.
16. Winkel P, Statland BE, Bokelund H. The effects of time of venipuncture on variation of serum constituents. Consideration of within-day and day-to-day changes in a group of healthy young men. Am J Clin Pathol. 1975;64:433-447.
17. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538.
18. MacFall JR, Wehrli FW, Breger RK, et al. Methodology for the measurement and analysis of relaxation times in proton imaging. Magn Reson Imaging. 1987;5:209-220.
19. Sugio S, Kashima A, Mochizuki S, et al. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 1999;12:439-446.
20. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. synthesis and characterization of the ligand BOPTA and Its Ln(II1) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-l-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer. Inorg Chem. 1995;34:633-642.
21. Rosenfeld RJ, Goodsell DS, Musah RA, et al. Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling. J Comput Aided Mol Des. 2003;17:525-536.
22. AutoDockTools. Available at: http://www.scripps.edu/mb/olson/doc/ autodock/.
23. CAT-program. Available at: http://www.md-simulations.de/cat/.
24. Deleted in proof.
25. Bombieri G, Artali A. The impact of lanthanide(III) derivatives on biological systems. Journal of Alloys and Compounds. 2002;9-16.
26. Dundee PRODRG2. Available at: http://davapc1.bioch.dundee.ac.uk/ programs/prodrg/. 2005.
27. Frömmel PFW, Nakamura C, Sander C. An effective solvation term based on atomic occupancies for use in protein simulations. Molecular Simulation. 1993;10:97-120.
28. Curry S, Mandelkow H, Brick P, et al. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol. 1998;5:827-835.
29. Stanisz GJ, Henkelman RM. Gd-DTPA relaxivity depends on macromolecular content. Magn Reson Med. 2000;44:665-667.
30. Vander Elst L, Laurent S, Muller RN. Multinuclear magnetic resonance characterization of paramagnetic contrast agents. The manifold effects of concentration and counterions. Invest Radiol. 1998;33:828-834.
31. Herborn CU. On the difference between 0.5-M and 1.0-M gadolinium chelates for 3D MR angiography. Eur Radiol. 2004;14(suppl 5):M21-M22.
32. Huppertz, A. Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol. 2004;14(suppl 5):M12-M18.
33. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702.
34. Sardanelli F. MultiHance for dynamic MR imaging of the breast. Eur Radiol. 2004;14(suppl 7):O65-O70.
35. Ajaj WM, Lauenstein TC, Pelster G, et al. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut. 2005;54:257-263.
36. Essig M, Giesel F, Le Huu M, et al. Perfusion MRI in CNS disease: current concepts. Neuroradiology. 2004;46(suppl 2):s201-s207.
37. Lowe A, Balzer T, Hirt U. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol. 2005;40:521-525.
38. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005;234:399-408.
39. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713-725.
40. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
41. Boos M, Scheffler K, Haselhorst R, et al. Arterial first pass gadolinium-CM dynamics as a function of several intravenous saline flush and Gd volumes. J Magn Reson Imaging. 2001;13:568-576.
42. Boos M, Scheffler K, Haselhorst R, et al. Arterial first pass gadolinium-CM dynamics as a function of several intravenous saline flush and Gd volumes. J Magn Reson Imaging. 2001;13:568-576.